Our site uses cookies, view our cookie policy. To view the site without this banner, you must accept our cookie usage.

Research Expedition to Everest a Success

Dr Boos has recently returned from a 3 week research expedition in April -May 2011 to the Himalayas culminating in a final climb to the peak of Kala Patthar at just over 18,500 ft opposite Mount Everest. His projects were all focussed on the effects of low oxygen and high altitude on the heart and included assessments of heart rhythm activity, arterial stiffness/vascular tone and cardiac performance using echocardiography. He is indebted to to the help of the supporting team and expedition leaders for allowing this very difficult and challenging project to happen and thanks the key sponsors: Poole Rotary Club, Sonosite, Spacelabs, GE Healthcare and the MOD. 

South Coast Heart Failure Meeting 2011

The annual South Coast Heart Failure Meeting will be held this year at the Haven Hotel on the 7th April 2011.

South Coast Heart Failure Meeting 2010

This meeting was held on the 30th March 2010 at the Haven Hotel, Sandbanks, Poole, Dorset and was organised by Dr Boos, Consultant Cardiologist, Poole and BMI Hospitals. There 84 attendees and the one-day programme covered a wide variety of heart failure related topics: these included the use of cardiopulmonary exercise testing - CPEX, CPET, CPX - in heart failure, updates on imaging, device therapy and surgery in heart failure and on the very topical issue of atrial fibrillation in heart failure. The meeting was appproved by the Royal College of Physicians for Continuing Professional Development. Following on from the meetings's success it is hoped that this it might become an annual event open to heart failure clinicans, cardiologists and nurse specialists practising along the South Coast and Wessex.


Dronedarone Approved by NICE

The UK National Institute for Clinical Excellence (NICE) has issued a second draft guidance on the 30th March 2010 on the new antiarrhythmic agent dronedarone (Multaq, Sanofi-Aventis), revising its original recommendation that the drug should not be used to treat atrial fibrillation (AF). This drug is likely to be available for use on the NHS within months and will be indicated for certain subgroups of patients suffering with AF.  For the full guidance see the NICE website at  www.nice.org.uk/.

Ivabradine Shows Promise in Heart failure Treatment: the SHIFT Study

The results of the recent SHIFT study published in the Lancet on 29 August 2010 support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the important role of heart rate in the pathophysiology of this disorder: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61198-1/abstract 



This trial recently publsihed its results demonstrating that the tablet Eplerenone (versus placebo), taken once daily, in addition to standard heart failure medication, significantly reduced the primary endpoint of death or admisssion to hospital with heart failure among patients with mild heart failure symptoms  www.nejm.org/doi/pdf/10.1056/NEJMoa1009492